MOTS-c: The Mitochondrial-Derived Peptide Regulating Metabolism and Aging

MOTS-c represents a paradigm shift in our understanding of cellular communication and metabolic regulation. Discovered in 2015 by Dr. Changhan Lee and colleagues at the University of Southern California, this 16-amino-acid peptide is encoded not by nuclear DNA but within the mitochondrial genome itself—specifically within the MT-RNR1 gene that also produces the 12S ribosomal RNA. As the first characterized mitochondrial-derived peptide (MDP) with demonstrated hormone-like signaling functions, MOTS-c has opened entirely new avenues for understanding how mitochondria communicate with the rest of the cell and regulate systemic metabolism.

Discovery and Molecular Origins

The discovery of MOTS-c challenged the traditional view of mitochondria as mere energy-producing organelles. Using bioinformatic analysis of mitochondrial open reading frames (ORFs), Lee’s team identified a small coding sequence within the 12S rRNA region that could produce a functional peptide. The resulting compound—MOTS-c—was found to be highly conserved across mammalian species, suggesting strong evolutionary pressure to maintain its function.

The amino acid sequence of MOTS-c is MRWQEMGYIFYPRKLR, a hydrophobic peptide that can traverse cellular membranes and signal to distant tissues. According to research published in Wikipedia and Cell Metabolism, this peptide is produced in response to metabolic stress and exercise, functioning as a mitokine that coordinates adaptive responses across multiple organ systems.

Mechanism of Action: AMPK Activation

The primary molecular target of MOTS-c is the AMP-activated protein kinase (AMPK) pathway—a master regulator of cellular energy status. When ATP levels decline and AMP levels rise, AMPK activates catabolic pathways while inhibiting anabolic processes, essentially switching the cell into “energy conservation mode.” MOTS-c potently activates this pathway, mimicking the metabolic effects of exercise and caloric restriction.

Research published in PubMed (Lee et al., 2015) and Cell Metabolism demonstrates that MOTS-c increases cellular levels of 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR)—a well-known AMPK activator—leading to downstream phosphorylation and activation of the kinase. This activation cascade triggers multiple metabolic adaptations:

• Enhanced Glucose Uptake: Upregulation of GLUT4 transporters in skeletal muscle, improving insulin-independent glucose disposal
• Increased Fatty Acid Oxidation: Shift toward lipid metabolism for energy production
• Mitochondrial Biogenesis: Activation of PGC-1α and other regulators of mitochondrial proliferation
• Glycolytic Regulation: Optimization of glucose metabolism pathways

These effects position MOTS-c as a central player in metabolic homeostasis with implications for diabetes, obesity, and metabolic syndrome research.

Insulin Sensitivity and Glucose Homeostasis

One of the most significant findings in MOTS-c research is its ability to prevent and reverse insulin resistance. In landmark mouse studies, treatment with the peptide prevented high-fat-diet-induced insulin resistance and obesity, even when animals consumed excess calories. This suggests that MOTS-c can uncouple metabolic dysfunction from caloric intake—addressing the underlying cellular mechanisms rather than simply reducing energy availability.

Studies documented in Frontiers in Physiology confirm that MOTS-c improves insulin sensitivity in skeletal muscle by activating AMPK signaling and upregulating GLUT4 expression. This enables efficient glucose uptake and metabolism independent of insulin receptor activation, providing an alternative pathway for glucose disposal that remains functional even in insulin-resistant states.

Additionally, research in NIH/PMC demonstrates that MOTS-c prevents pancreatic islet cell senescence—potentially delaying the onset of type 2 diabetes by preserving beta-cell function and insulin secretion capacity.

Exercise Mimetic Effects

MOTS-c has been described as an “exercise mimetic” because it activates many of the same molecular pathways stimulated by physical activity. During exercise, contracting muscles release MOTS-c into circulation, where it signals to distant tissues including fat, liver, and heart. This endocrine-like function coordinates whole-body metabolic adaptation to physical activity.

Research published in Nature Communications shows that MOTS-c treatment in aged mice improved physical capacity, enhanced muscle homeostasis, and compressed morbidity—effects similar to those achieved through exercise training. The peptide appears to restore metabolic flexibility that declines with age, enabling older tissues to respond appropriately to energy demands.

Key exercise-like effects include:

• AMPK activation in multiple tissues
• Enhanced fatty acid oxidation
• Improved mitochondrial efficiency
• Increased expression of mitochondrial biogenesis markers
• Protection against metabolic stress

However, researchers note that MOTS-c does not replicate all benefits of exercise and should be viewed as complementing rather than replacing physical activity.

Aging and Longevity Research

Circulating levels of MOTS-c decline with age in both humans and animal models, paralleling the metabolic dysfunction and insulin resistance that characterize aging. This age-dependent reduction has positioned the peptide as a potential biomarker of metabolic aging and a target for intervention.

Studies documented in Aging reveal that skeletal muscle expression of MOTS-c varies with age and physical fitness, with higher levels associated with better muscle quality and metabolic health in older adults. The peptide appears to function as a compensatory response to age-related metabolic stress, coordinating transcriptional programs that maintain cellular function.

Preclinical research suggests that restoring MOTS-c levels in aged animals can reverse age-dependent physical decline, improve glucose tolerance, and extend healthspan. These findings have generated significant interest in the peptide’s potential for addressing age-related metabolic diseases.

Anti-Inflammatory and Oxidative Stress Protection

Beyond metabolic regulation, MOTS-c demonstrates protective effects against inflammation and oxidative stress. Research published in Frontiers in Endocrinology indicates that the peptide can inhibit oxidative stress, modulate NF-κB signaling, and protect against endothelial dysfunction.

These anti-inflammatory properties complement its metabolic effects, as chronic inflammation and oxidative stress are key drivers of insulin resistance and metabolic disease. By addressing multiple pathological processes simultaneously, MOTS-c offers a multifaceted approach to metabolic health.

Clinical Development and Human Research

While most MOTS-c research has occurred in preclinical models, human studies have begun to translate these findings. Observational research has established correlations between circulating MOTS-c levels and metabolic health parameters in human populations. Lower levels are associated with insulin resistance, obesity, and metabolic syndrome.

A Phase 2a randomized, double-blind, placebo-controlled clinical trial (NCT07505745) is currently investigating MOTS-c in adults with prediabetes and overweight or obesity. This study represents the first rigorous test of the peptide’s efficacy in human metabolic disease and will provide critical data on safety, optimal dosing, and therapeutic potential.

For researchers investigating mitochondrial signaling, metabolic regulation, and exercise physiology, MOTS-c offers a unique tool for probing the interface between mitochondrial function and systemic metabolism. Browse our complete research peptide catalog at Buy Nova Peptides Shop or visit Buy Nova Peptides for additional resources.

References and Scientific Literature

1. Lee, C., et al. (2015). “The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.” Cell Metabolism, 21(3), 443-454. PubMed
2. Reynolds, J.C., et al. (2021). “MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.” Nature Communications, 12, 1834. Nature Communications
3. Lu, H., et al. (2025). “Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes.” Experimental & Molecular Medicine. NIH/PMC
4. Kim, S.J., et al. (2023). “MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation.” Frontiers in Endocrinology, 14, 1120533. Frontiers
5. Yang, B., et al. (2025). “Mitochondria-derived peptide MOTS-c restores mitochondrial respiration in type 2 diabetic heart.” Frontiers in Physiology. Frontiers
6. Trevisson, E., et al. (2021). “Increased expression of the mitochondrial derived peptide, MOTS-c, in skeletal muscle of healthy aging men is associated with myofiber composition.” Aging, 13(8), 11856-11869. Aging
7. ClinicalTrials.gov. “Study of MOTS-c in adults with prediabetes and overweight or obesity.” NCT07505745. ClinicalTrials.gov
8. Wikipedia Contributors. “MOTS-c.” Wikipedia. Wikipedia
9. Alzheimer’s Drug Discovery Foundation. “MOTS-c Research Summary.” ADDF
10. Google Scholar. “MOTS-c mitochondrial peptide AMPK exercise metabolism.” Google Scholar

Disclaimer: This content is provided for educational and research purposes only. MOTS-c is an investigational compound not approved for human consumption or therapeutic use. This information does not constitute medical advice, treatment recommendations, or claims of efficacy. Always consult qualified healthcare professionals and comply with applicable regulations governing research peptides.